Pharmaceutical firm, GlaxoSmithKline, expects a 10 per cent growth in Panadol sales this year.

Its Commercial Director for Malaysia and Singapore Lee Hon Tong said the company earned over 400 million ringgit revenue last year.

Panadol contributes more than a quarter of the total revenue to the company, which has invested three per cent of the contribution for research and development.

The brand, with a 88 per cent market share, has a variety of products such as Panadol Actifast, Menstrual and Panaflex.